Statement 5 Feb 2020

WHO EB 146 Agenda Item 7.1: Universal health coverage: moving together to build a healthier world

Delivered by David Gleicher (MSD) as part of the UHC 2030 Private Sector Constituency Geneva, 5 February, 2020: Universal Health Coverage means that all individuals and communities have access to quality essential health services without risk of financial hardship. The private sector is well-positioned to contribute to UHC efforts and already provides health products and...

Read more
Statement 4 Feb 2020

WHO EB 146 Agenda Item 22.2: Engagement with non-State actors / Report on implementation of the Framework of Engagement with Non-State Actors

Delivered by Vanessa Peberdy, Head of NCD Policy & Advocacy & WHO Engagement Geneva, 4 February 2020: This Statement is made by the International Federation of Pharmaceutical Manufacturers and Associations, the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association, the Global Self-Care Federation, supported by the International Council of Biotechnology Associations. We represent key...

Read more
Position paper 4 Feb 2020

IFPMA Note for Guidance on Fees for Services (2020 update)

The Ethos of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is centered on trust to “act with integrity and honesty to improve patient care and build trust with those we serve and to respect the independence of healthcare providers, patients and other stakeholders”. The purpose of this document is to provide additional interpretation...

Read more
Note for Guidance: Fees for Services
Statement 3 Feb 2020

Biopharmaceutical Industry Response to 2019-nCoV Acute Respiratory Disease

Geneva, 31 January 2020: The research-based biopharmaceutical industry (IFPMA and its members) is deeply concerned by the coronavirus (2019-nCoV acute respiratory disease) epidemic. Outbreaks of novel virus infections for which there is no known effective antiviral therapy present a serious threat to public health. IFPMA and its members stand together in support with the global...

Read more
Statement 30 Jan 2020

IFPMA Statement on the G-FINDER report 2019

G-FINDER report: Investment in neglected disease R&D by multinational pharmaceutical companies grew by more than a quarter in 2018, reaching its highest-ever level Geneva, 30 January 2020: IFPMA, the global R&D biopharmaceutical industry association, welcomes the 2019 G-FINDER report, which tracks public, private and philanthropic investment into product R&D for neglected diseases. The report shows...

Read more
Expert insight 29 Jan 2020

Creating Synergies To Beat Neglected Diseases

This article was originally published in Life Science Leader on January 29, 2020. A staggering 1.5 billion people, each year, are treated for a neglected tropical disease (NTDs). These diseases can be painful, blinding and disfiguring, keeping children out of school and adults out of work, are often attached to stigma in some community. These diseases are...

Read more
Expert insight 21 Jan 2020

Five Questions to …. Dr. Lembit Rägo

This year IFPMA is hosting its 10th Asia Regulatory Conference (ARC2020) in Kuala Lumpur. The Council for International Organizations of Medical Sciences (CIOMS) is represented in the conference Advisory Board by Dr Lembit Rägo, its Secretary General. IFPMA sat down with Dr Rägo to discuss CIOMS’s activities, future of the biopharmaceutical industry and the future...

Read more
Press release 16 Jan 2020

AMR life science industry 2020 report: Successes and setbacks in fighting superbugs

AMR Industry Alliance reports breakthroughs in the responsible manufacturing of antibiotics and positive steps to improve how patients access and use antibiotics. But its report also highlights concerning levels of research and development (R&D) investment. Alliance records US$6bn annual investment (in 2018) in antimicrobial resistance (AMR)-relevant R&D. Concerning shortfall is in late stage R&D investment...

Read more
Report 16 Jan 2020

AMR Industry Alliance 2020 progress report

Read more
Expert insight 7 Jan 2020

Promoting Regulatory Collaboration and Convergence in Asia

This article was originally published in Pharma Focus Asia in December 2019. Regulatory reliance is increasingly being used by National Regulatory Authorities (NRAs) with different regulatory systems and is actively promoted by the World Health Organization (WHO) as a mechanism to better manage resource capacity issues and strengthen regulatory systems. NRAs in Asia remain key...

Read more
Expert insight 6 Dec 2019

Five Questions to …. Andréa Vassalotti

On the occasion of Fight the Fakes Week 2019, we talked to Andrea Vassalotti, Director of Partnerships and Programmes at the World Heart Federation (WHF), about the importance of recognizing the issue of substandard and falsified medicines as a public health threat, and the efforts that must be made to  address the problem effectively. Why...

Read more
Expert insight 3 Dec 2019

Five questions to …. Dr. Githinji Gitahi

This year’s theme for International Universal Health Coverage (UHC) Day is “Keep the Promise”. We sat down with Dr Githinji Gitahi, CEO of Amref Health Africa and co-chair of the UHC2030 Steering Committee to discuss how to operationalise and finance UHC after the various global commitments and plans to achieve UHC that took place this...

Read more